HDAC2 and hepatocellular carcinoma: Studies have revealed that the TGF-β signaling-upregulated noncoding RNA HDAC2-AS2 in HBV+HCC targets CDK9 in CD8+ T cells via exosomes, compromising their function and offering a novel therapeutic target for HBV-associated HCC[52].